The drug etanercept shows no benefit against the autoimmune disorder Wegener’s granulomatosis, according to results of a clinical trial led by Johns Hopkins researchers.The study was designed to evaluate the ability of the drug, also called Enbrel, to maintain disease remission. The study included 180 patients with Wegener’s -- 89 of them received etanercept and 91 received a placebo. The patients were followed for an average of 27 months.There was no significant difference in the percentages of patients in the two groups who achieved at least six months of disease remission -- 69.7 percent in the group that received the drug and 75.3 percent in the control group.The study also found no difference between the two groups in the numbers of patients who experienced severe or limited flare-ups of their disease.The findings appear in the Jan. 27 issue of the New England Journal of Medicine.Etanercept, the first of a class of drugs called tumor necrosis factor inhibitors approved by the U.S. Food & Drug Administration for the treatment of rheumatoid arthritis, is also known to be effective in psoriasis, psoriatic arthritis and juvenile rheumatoid arthritis.
